Page 646 - Cardiac Nursing

0/2
0/2
6/3
0
6/3
009
7:4
7:4
1
009
1
22.
q
22.
5-6
5-6
q
0
0
xd
q
xd
A
p
A
22
A
p
ara
ara
t
p
t
Pa
Pa
Pa
5
5
g
e 6
22
e 6
g
g
p
25_
p
59
59
LWB
LWB K34 0-c 25_ pp595-622.qxd 06/30/2009 17:45 Page 622 Aptara
LWBK340-c25_
0-c
K34
622 PA R T I V / Pathophysiology and Management of Heart Disease
64. Shumway, N. E., Lower, R. R., & Stofer, C. (1966). Transplantation of the official report-2002. Journal of Heart and Lung Transplantation, 21,
heart. Advances in Surgery, 2, 265–284. 950–970.
65. Trento, A., Takkenberg, J. M., Czer, L. S. C., et al. (1996). Clinical expe- 78. Valantine, H. A. (1995). Prevention and treatment of cytomegalovirus dis-
rience with one hundred consecutive patients undergoing orthotopic heart ease in thoracic organ transplant patients: Evidence for a beneficial effect
transplantation with bicaval and pulmonary venous anastomosis. Journal of hyperimmune globulin. Transplant Proceedings, 27, 49–57.
7
7
of Thoracic Cardiovascular Surgery, 112, 1496–1503. 79. Moran, M., Tomlanovich, S., & Myers, B. D. (1985). Cyclosporin-in-
66. Frazier, D. H., VanBuren, C. T., & Poindexter, S. M. (1985). Nutritional duced nephropathy in human recipients of cardiac allografts. Transplant
management of the heart transplant recipient. Heart Transplantation, 4, Proceedings, 17(Suppl. 1), 185–190.
4
7
7
4
450–452. 80. Myers, B. D., Ross, J., Newton, L., et al. (1984). Cyclosporin associated
67. Shinn, J. A. (1985). New issues in cardiac transplantation. In M. K. Dou- chronic nephrotoxicity. New England Journal of Medicine, 311, 699–705.
glas & J. A. Shinn (Eds.), Advances in cardiovascular nursing (pp. 81. Thompson, M. E., Shapiro, M. E., Johnsen, A. M., et al. (1983). New on-
185–195). Rockville: Aspen Systems. set of hypertension following cardiac transplantation. Transplant Proceed-
68. Bexton, R. S., Nathan, A. W., Hellestrand, K. J., et al. (1984). Sinoatrial ings, 25(Suppl. 1), 2573–2577.
function after cardiac transplantation. Journal of the American College of 82. Wagoner, L. W. (1997). Management of the cardiac transplant recipient:
Cardiology, 13, 712–723. Roles of the transplant cardiologist and primary care physician. American
4
4
69. DiBiase, A., Tse, T. M., Schnittger, I., et al. (1991). Frequency and mech- Journal of Medical Science, 324, 173–184.
anism of bradycardia in cardiac transplant recipients and need for pace- 83. Lough, M. E., Lindsey, A. M., Shinn, J. A. (1987). Impact of symptom
makers. American Journal of Cardiology, 67, 1385–1389. frequency and symptom distress on self-reported quality of life in heart
7
7
70. Rose, A. G. (1986). Endomyocardial biopsy diagnosis of cardiac rejection. transplant recipients. Heart and Lung, 16, 193–200.
6
6
Heart Failure, 2(2), 64–72. 84. Przepiorka, D. (1992). Tacrolimus: Preclinical and clinical experience. In
71. Stewart, S., Winters, G. L, & Fishbein, M. C. (2005). Revision of the D. Przepioka & H. Sollinger (Eds.), Recent developments in transplantation
1990 working formulation for the standardization of nomenclature in the medicine: New immunosuppressive drugs (pp. 29–50). Glenview, IL: Physi-
diagnosis of heart rejection. Journal of Heart and Lung Transplantation, 24, cians and Scientist Publishing.
4
4
1710–1720. 85. Lough, M. E., Lindsey, A. M., & Shinn, J. A. (1985). Life satisfaction fol-
4
4
72. Billingham, M. E., Cary, N. R. B., Hammond, M. E., et al. (1990). A lowing heart transplantation. Heart Transplantation, 4, 446–449.
working formulation for the standardization of nomenclature in the diag- 86. Crandell, B. (1990). Immunosuppression. In K. M. Sigardson-Poor & L.
nosis of heart and lung rejection: Heart rejection study group. Journal of M. Haggerty (Eds.), Nursing care of the transplant recipient (pp. 53–85).
Heart Transplantation, 9, 587–591. Philadelphia: WB Saunders.
73. Starling, R. C., Pham, M., Valantine, H., et al. (2006). Working 87. Eisen, H. J. (2003). Hypertension in heart transplant recipients: More
group on molecular testing in cardiac transplantation. Molecular test- than just cyclosporine. Journal of the American College of Cardiology, 41(3),
ing in the management of cardiac transplant recipients: Initial clinical 433–434.
experience. Journal of Heart and Lung Transplantation, 25(12), 88. Aranda, J. M., & Hill, J. (2000). Cardiac transplant vasculopathy. Chest,
1389–1395. 118, 1792–1800.
74. Uber, W. E., Self, S. E., Bakel, A. B., Van Bakel, A. B., & Pereira, N. C. 89. Sadowsky, H. S. (1996). Cardiac transplantation: A review. Physical Ther-
(2007). Acute antibody-mediated rejection following heart transplanta- apy, 76, 498–515.
6
6
tion. American Journal of Transplantation, 7, 2064–2074. 90. Sadowsky, H. S., & Fries, K. (1986). Introduction to the treatment of car-
7
7
75. Almuti, K., Haythe, J., Dwyer, E., Silviu, I., et al. (2007). The changing diac and cardiopulmonary transplant patients. Stanford, CA: Department of
pattern of humoral rejection in cardiac transplant recipients. Transplanta- Physical and Occupational Therapy, Stanford University Hospital.
tion, 84, 498–503. 91. Shane, E., Addesso, V., Namerow, P. B., et al. (2004). Alendronate versus
4
4
76. Ramzy, D., Rao, V., Brahm, J., et al. (2005). Cardiac allograft vasculopa- calcitrol for the prevention of bone loss after cardiac transplantation. New
thy: A review. Canadian Journal of Surgery, 48, 319–327. England Journal of Medicine, 350, 767–769.
77. Hertz, M. I, Taylor, D. O., Trulock, E. P., et al. (2002). The Registry of 92. Rodino, M. A., & Shane, E. (1998). Osteoporosis after organ transplanta-
the International Society for Heart and Lung Transplantation: Nineteenth tion. American Journal of Medicine, 104(5), 459–469.